drugset / Trial / NCT01997879

Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy Volunteers

NCT01997879

Phase 1 Completed 18 enrolled Aerie Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess systemic safety and absorption of AR-13324 in healthy volunteers.

Timeline

Start
2013-11
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Netarsudil Small molecule 0.02 % Other

Indications

No indication recorded.